ROCHESTER, N.Y., Mar 30, 2005 (BUSINESS WIRE) --Biophan Technologies, Inc. (OTCBB: BIPH), a developer of next-generation biomedical technology, today filed an SEC Form 8-K containing the transcript of a recent online interview given by Company CEO Michael Weiner.
In the interview, Mr. Weiner states that the newly filed and issued patents are part of Biophan's continued strategy to build a market-dominating " patent thicket." These patent thickets are intended to help ensure broad protection for both the Company and for any partners that use Biophan's technology in the manufacture of biomedical solutions and products. " If someone partners with us on an exclusive basis, they'll have a really strong position to defend their market turf as we build the market together," he said.
Mr. Weiner added that Biophan's intellectual property portfolio currently represents a significant competitive advantage for the Company. Biophan's intellectual property portfolio of 114 patents, licenses, and applications includes 34 issued patents and 8 allowed applications. The Company recently filed 6 new patent applications, bringing the patents pending total to 72. The patents provide solutions to improve the safety, effectiveness, and image compatibility of medical devices used within Magnetic Resonance Imaging (MRI) environments, as well as a variety of solutions, such as nanotechnology, to create competitively advantageous product enhancements in several markets, including drug-elution technologies and implantable power systems powered by body heat. " This relates to staying several years ahead of the rest of the industry, so that as these new markets emerge for minimally invasive surgery imageable devices, we're the dominant factor in the industry," said Mr. Weiner. " That's our hope and so far we're probably over 100 patents ahead of everybody else in the industry, combined."
The two most recently issued patents can be viewed at www.biophan.com/6864418.html and www.biophan.com/6847837.html.
The interview transcript can be read in the Company's SEC Form 8-K, filed today. The audio version of the interview can be accessed at www.SmallcapInsights.com.
Hier beweist Weiner mal wieder wie taktisch geschickt er ist!!Die Firmen kommen nicht an Biophan vorbei,da Biophan das Produkt und das Patent hat.
Nach dieser Meldung laufen wir heute locker über 3$.Biophan nimmt auch an einer Konferenz teil, wo es um 12 unterbewertete Firmen geht.
Heute geht es nochnmal locker ab.
manager01 
Yours sincerly, TheArtistFormerlyKnownAsRalph&zeitraum=6&bname=&bis=1129739712.53921&zeitvon=&typ=1&ind_adhoc=&ind_gd200=OFF&skalierung=log&beingabe=Name%2C%20WKN%2C%20ISIN&zeitbis=&cookies=HASH(0xa27242c)&ind_volume=ON&boerse_id=1&ago=Aktualisieren&go=go&von=0&banner_ref=HASH(0x9c69c84)&req_host=www.ariva.de&b=&ind_gd38=ON "ariva.de")
